FAQ   Contact Us   Forward to a Friend   
      

Resources

The advanced HelitraxSM System is true, wireless, mobile technology designed to strengthen the connection between you, your patients, and their Helixate® FS therapy. This one-of-a-kind data management system enables you and your patients to improve the overall management of their disease…working together as a team.

In addition to the benefits of proven efficacy and safety, patients on Helixate® FS can now have a friendlier experience managing their therapy with the new HelitraxSM System.1–4

You and your patients stay in touch

  • True wireless, Internet-based electronic diary makes data entry easy and offers patients the peace of mind that comes with a dependable connection to their HTC team
  • Data compiled in one report for a clear, clinical snapshot of your patient

Treatment stays on track

  • Access to patient data before and between visits enables you to address any complications or concerns patients may have with treatment
  • Emergency bleeding events can be rapidly assessed with high-priority messaging and picture-taking capabilities

Closer to improved patient care with a comprehensive view of your patient’s clinical picture

  • Continuous tracking of medication usage, inventory, bleeding events, and follow-up—all graphically displayed in one report
  • Clinical assessment of your patient—before and between visits
  • Rapid assessment of bleeding events anywhere and at any time with built-in camera feature
      –   Sends a high-priority message directly to your treatment center      in emergency bleeding event situations
      –   Describes in detail the specifics of a bleeding event, complete      with location, symptoms, and picture

Closer to the data management needs of your treatment center

  • Reduces the chance of documentation and transcription errors
  • Saves time by eliminating paperwork and directing only high-priority messages to your attention
  • Provides a JACHO-compliant progress report for patient’s medical records

For more information about the HelitraxSM System, please call CSL Behring Consumer Affairs at 1-888-508-6978.

  1. 1. Kreuz W, Gill JC, Rothschild C, et al, and the International Kogenate-FS Study Group. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005;93:457–467.
  2. 2. Oldenburg J, Ivaskevicius V, Schröder J, Müller CR, Ganguly A. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost. 2006;95:903–905.
  3. 3. Abshire TC, Brackmann H-H,Scharrer I, et al, and the International Kogenate-FS Study Group. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: results of a multicenter, international, clinical investigation. Thromb Haemost. 2000;83:811–816.
  4. 4. Data on file, Bayer Corporation.